New safety data for leukemia drug BESPONSA in 421 patients
NCT ID NCT05923112
First seen Jan 04, 2026 · Last updated May 18, 2026 · Updated 26 times
Summary
This study looked at the safety of BESPONSA, a drug already approved for a type of blood cancer called acute lymphocytic leukemia that has come back or not responded to treatment. Researchers tracked 421 patients in Japan who received the drug as part of their regular care. The main goal was to record side effects, especially liver problems, low blood counts, infections, and bleeding. This was not a test of whether the drug cures the disease, but rather a check on its real-world safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.